University of Wollongong

Research Online
Faculty of Science, Medicine and Health - Papers

Faculty of Science, Medicine and Health

2017

Medication adherence in randomized controlled
trials evaluating cardiovascular or mortality
outcomes in dialysis patients: A systematic review
Karumathil Murali
University of Wollongong, kmurali@uow.edu.au

Judy Mullan
University of Wollongong, jmullan@uow.edu.au

Jenny H. Chen
University of Wollongong, chenj@uow.edu.au

Steven J. Roodenrys
University of Wollongong, steven@uow.edu.au

Maureen A. Lonergan
University of Wollongong, maureenl@uow.edu.au

Publication Details
Murali, K., Mullan, J., Chen, J., Roodenrys, S. & Lonergan, M. (2017). Medication adherence in randomized controlled trials
evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review. BMC Nephrology, 18 (1), 1-11.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

Medication adherence in randomized controlled trials evaluating
cardiovascular or mortality outcomes in dialysis patients: A systematic
review
Abstract

Background: Medication non-adherence is common among renal dialysis patients. High degrees of nonadherence in randomized controlled trials (RCTs) can lead to failure to detect a true treatment effect. Cardioprotective pharmacological interventions have shown no consistent benefit in RCTs involving dialysis
patients. Whether non-adherence contributes to this lack of efficacy is unknown. We aimed to investigate how
medication adherence and drug discontinuation were assessed, reported and addressed in RCTs, evaluating
cardiovascular or mortality outcomes in dialysis patients.
Methods: Electronic database searches were performed in MEDLINE, EMBASE & Cochrane CENTRAL for
RCTs published between 2005-2015, evaluating self-administered medications, in adult dialysis patients,
which reported clinical cardiovascular or mortality endpoints, as primary or secondary outcomes. Study
characteristics, outcomes, methods of measuring and reporting adherence, and data on study drug
discontinuation were analyzed.
Results: Of the 642 RCTs in dialysis patients, 22 trials (12 placebo controlled), which included 19,322
patients, were eligible. The trialed pharmacological interventions included anti-hypertensives, phosphate
binders, lipid-lowering therapy, cardio-vascular medications, homocysteine lowering therapy, fish oil and
calcimimetics. Medication adherence was reported in five trials with a mean of 81% (range: 65-92%) in the
intervention arm and 84.5% (range: 82-87%) in the control arm. All the trials that reported adherence yielded
negative study outcomes for the intervention. Study-drug discontinuation was reported in 21 trials (mean
33.2%; 95% CI, 22.0 to 44.5, in intervention and 28.8%; 95% CI, 16.8 to 40.8, in control). Trials with more
than 20% study drug discontinuation, more often yielded negative study outcomes (p = 0.018). Nonadherence was included as a contributor to drug discontinuation in some studies, but the causes of
discontinuation were not reported consistently between studies, and non-adherence was listed under different
categories, thereby potentiating the misclassification of adherence.
Conclusions: Reporting of medication adherence and study-drug discontinuation in RCTs investigating
cardiovascular or mortality endpoints in dialysis patients are inconsistent, making it difficult to compare
studies and evaluate their impact on outcomes. Recommendations for consistent reporting of non-adherence
and causes of drug discontinuation in RCTs will therefore help to assess their impact on clinical outcomes.
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Abstract
Background: Medication non-adherence is common among renal dialysis patients. High degrees of non-adherence
in randomized controlled trials (RCTs) can lead to failure to detect a true treatment effect. Cardio-protective
pharmacological interventions have shown no consistent benefit in RCTs involving dialysis patients. Whether
non-adherence contributes to this lack of efficacy is unknown. We aimed to investigate how medication
adherence and drug discontinuation were assessed, reported and addressed in RCTs, evaluating cardiovascular
or mortality outcomes in dialysis patients.
Methods: Electronic database searches were performed in MEDLINE, EMBASE & Cochrane CENTRAL for RCTs published
between 2005–2015, evaluating self-administered medications, in adult dialysis patients, which reported clinical
cardiovascular or mortality endpoints, as primary or secondary outcomes. Study characteristics, outcomes, methods of
measuring and reporting adherence, and data on study drug discontinuation were analyzed.
Results: Of the 642 RCTs in dialysis patients, 22 trials (12 placebo controlled), which included 19,322 patients,
were eligible. The trialed pharmacological interventions included anti-hypertensives, phosphate binders, lipid-lowering
therapy, cardio-vascular medications, homocysteine lowering therapy, fish oil and calcimimetics. Medication adherence
was reported in five trials with a mean of 81% (range: 65–92%) in the intervention arm and 84.5% (range: 82–87%) in
the control arm. All the trials that reported adherence yielded negative study outcomes for the intervention.
Study-drug discontinuation was reported in 21 trials (mean 33.2%; 95% CI, 22.0 to 44.5, in intervention and 28.8%;
95% CI, 16.8 to 40.8, in control). Trials with more than 20% study drug discontinuation, more often yielded negative
study outcomes (p = 0.018). Non-adherence was included as a contributor to drug discontinuation in some studies, but
the causes of discontinuation were not reported consistently between studies, and non-adherence was listed under
different categories, thereby potentiating the misclassification of adherence.
Conclusions: Reporting of medication adherence and study-drug discontinuation in RCTs investigating cardiovascular
or mortality endpoints in dialysis patients are inconsistent, making it difficult to compare studies and evaluate their
impact on outcomes. Recommendations for consistent reporting of non-adherence and causes of drug discontinuation
in RCTs will therefore help to assess their impact on clinical outcomes.
Keywords: Cardiovascular outcomes, Dialysis, Medication adherence, Study drug discontinuation, Mortality, Randomized
controlled trials
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Background
Poor adherence to treatment is an important problem in
the management of chronic diseases [1]. Non-adherence
is widely prevalent, yet, frequently under-recognized and
is associated with higher mortality and morbidity, as
well as increased treatment costs [2]. Non-adherence
is multi-dimensional and determined by five major
interacting domains; namely socio-economic, health
care system related, therapy related, disease related
and patient related factors [1]. Poor socio-economic
status, complexity of treatment regimen, poor health
literacy and comorbidities (such as depression and
cognitive impairment) predispose patients with end
stage kidney disease (ESKD) on dialysis to become
non-adherent with their medications [3, 4]. The problem
can be particularly challenging, when poor adherence
doesn’t have any noticeable short-term effect on symptoms [5]. Poor treatment adherence is predictive of
increased mortality among dialysis patients [4], but the
reporting of adherence in clinical trials involving dialysis
patients is inconsistent.
Cardiovascular mortality is 10–20 fold greater in dialysis
patients, compared to age and sex-matched controls
without chronic kidney disease (CKD) [6]. Traditional
risk factors account for up to 50% of cardiovascular disease in CKD [7], while non-traditional factors unique
to renal disease, like anemia, disordered bone mineral
metabolism and oxidative stress, also contribute to poor
cardiovascular outcomes. Trials evaluating cholesterol
lowering medications like HMG-CoA reductase inhibitors,
which have proven efficacy in reducing cardiovascular
outcomes in the general population, have shown no significant benefits in patient on dialysis [8–11]. Modification
of the risk factors like correction of anaemia [12], homocystine lowering therapies [13], treatment with omega-3
fatty acids [14], control of hyperphosphataemia [15, 16],
and treatment of secondary hyperparathyroidism [17]
have also shown no consistent benefit in improving
cardiovascular mortality or significant clinical events
in dialysis patients. To explain this lack of efficacy of
cardio-protective pharmacological interventions, it has
been suggested that the pathogenesis of cardiovascular
disease in ESKD, might be different from that in the
general population, making it less amenable to interventions [6]. Whether poor medication adherence contributes to the lack of efficacy of these pharmacological
interventions is unknown. In clinical trial settings, a
high frequency of non-adherence (i.e. failure to adhere
to prescribed treatments) can result in failure to detect
a true difference, due to the loss of statistical power [18].
In addition, a high frequency of study drug discontinuation, which can be due to poor treatment adherence as
well as several factors, such as adverse events, drop-out
from the study or withdrawal due to protocol specified
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events like kidney transplantation, can also lead to a false
negative study outcome due to loss of statistical power.
Consistent reporting of the causes of drug discontinuation
is needed to compare studies with respect to the contribution of non-adherence to discontinuation and evaluate
their impact on clinical outcomes.
In this review, we sought to examine whether the
important issue of adherence to prescribed treatment
and study drug discontinuation were adequately and
consistently assessed, reported and appropriately addressed
in the randomized clinical trials (RCTs) evaluating selfadministered cardioprotective medications compared to
controls (placebo, another active medication or usual
care) in improving cardiovascular or mortality outcomes
in patients undergoing dialysis.

Methods
We included all RCTs published as full-text journal articles,
over a ten-year period (2005–2015) in this systematic
review. The time period was chosen because of the improved awareness of the need to monitor medication
adherence in clinical outcomes of intervention trials in
recent years. The studies that investigated the effect of
any self-administered pharmacological treatment in
ESKD patients undergoing dialysis, and reported clinical
cardiovascular events or mortality, as the pre-specified
primary or secondary outcomes were included.
a. Search strategy

Electronic database searches were performed in MEDLINE,
EMBASE and Cochrane CENTRAL register of controlled
trials for articles published in English, from 2005 onwards
using standard search strategies. Medical subject headings
included: ‘clinical trial’, ‘trial’, ‘randomized trial’, ‘single blind’
or ‘double blind’; ‘cardiovascular disease’, ‘cardiovascular outcome’, or ‘mortality’; and ‘dialysis’, ‘renal dialysis’ or ‘peritoneal dialysis’, with the search limited to between 1st January
2005-31st December 2015. Search results in the form of
titles and abstracts were analyzed by two authors (KM, JC)
to ensure inter-rater agreement, regarding which studies to
include in the final review, based on inclusion criteria outlined below. Any disagreement was resolved by discussion
among all authors. References within included articles and
other important reviews regarding the topic were handsearched to identify reports that might have been missed in
the previous search.
b. Study selection criteria and characteristics

Studies published as full-text articles that included ESKD
patients undergoing haemodialysis or peritoneal dialysis
alone were considered eligible. Trials, that recruited both
dialysis and non-dialysis patients were included, only if
the article provided information on the mortality or cardiovascular outcomes for the sub-group of participants on
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dialysis. This review included only trials comparing a selfadministered pharmacological intervention to a control
therapy (placebo, another active therapy or usual care).
The pre-specified primary or secondary outcomes had to
report at least one clinical cardiovascular outcome, which
could include fatal or non-fatal cardiovascular events, a
composite or death due to any cause. Studies reporting
surrogate cardiovascular endpoints, including radiological
(e.g. vascular calcification) or biochemical markers (e.g.
troponin levels) of cardiovascular disease, as the only
primary or secondary outcome were excluded.
c. Data abstraction and synthesis

A standard check-list, for specific data as described below,
was used to abstract information from the included studies.
Two authors (KM, JC) abstracted data to generate independent datasheets, comprising of quantitative and qualitative information, which were compared to verify inter-rater
agreement.
The abstracted data from each study included the: year
of publication; journal; first author’s surname; funding
source; study acronym; study period; number of participants in the intervention and control arms; study
population; inclusion and exclusion criteria; the trialed
intervention and control treatments; primary and secondary outcomes; randomization method; information
on allocation concealment; blinding of participant, investigator and/or outcome assessment; analysis type
(e.g. intention to treat); completeness of outcome data;
likelihood of selective reporting; follow-up duration;
drop-out rate; whether the study was positive or negative for the outcome of interest; significant secondary
outcomes; and reported death from all causes.
We specifically examined whether medication adherence
was evaluated, reported and addressed in the included
trials. If reported, the method of measuring adherence and
its prevalence were assessed. Any method of measurement
of individual patient’s adherence was considered acceptable.
We recorded the number of subjects discontinuing study
medication during the course of the study, reasons for
study medication withdrawal and whether non-adherence
was identified as a contributor. Where medication adherence was not reported in an article, we contacted
the authors to understand whether it was evaluated in
the trial. All authors were asked the same question:
whether medication adherence was assessed, if yes,
what method was used and what was the reported level
of adherence.
d. Statistical methods

Inter-rater reliability was assessed using Cohen’s kappa
statistics. The average medication adherence and study
drug discontinuation from the included trials were
reported as a mean percentage. Proportions were
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expressed as percentages and Fisher’s exact test was
used to compare proportions. The analyses were conducted using Stata® version 12.1.

Results
a. Trial flow

Electronic searches of all three databases returned 2417
reports, and after excluding non-intervention and nonrandomized studies, 642 articles were identified. Out of
this, 22 trials were included in the final analysis in
accordance with the specified inclusion and exclusion
criteria (Fig. 1).
b. Description of studies

Nineteen (86%) trials recruited patients on haemodialysis
only, while the remaining trials [9, 11, 19] enrolled dialysis
and non-dialysis patients. In this latter group however,
separate outcomes data were provided for the dialysis
patients.
The pharmacological intervention varied among the
22 included trials. Six studies [20–25] evaluated antihypertensive medications, four studies trialed lipid
lowering agents [8–11], four studies trialed phosphatebinding drugs [15, 16, 26, 27] three studies trialed cardiovascular medications [28–30] including anti-platelet
agents, two studies trialed homocysteine lowering therapy
(folic acid) [19, 31], two studies trialed fish oil [14, 32] and
one study trialed calcimimetics [17].
Twelve of the 22 studies were double-blind placebo
controlled trials, while six trials compared the intervention with usual care as their control, and the remaining
four studies tested the intervention against another active
agent using an open-label design. Pharmaceutical sponsors were the main source of funding for nine studies,
which recruited a total of 15,166 dialysis patients, as
compared to the 4,156 patients recruited in the other
thirteen studies, funded by non-pharmaceutical sponsors.
A comprehensive summary of the 22 trials included in this
review is given in Table 1.
c. Estimation of risk of bias of the included studies

Was assessed using the criteria outlined in the Cochrane
handbook of systematic review of interventions [33].
Random allocation was followed for each of the 22
included studies and allocation concealment was
adequate in 14 of the studies (64%). Twelve studies
(55%) described blinding of participants and caregivers
and the blinding of outcome assessments were specified in 18 of the studies (82%). The ‘intention to treat’
principle of analysis was used in almost all of the studies (n = 20; 91%). Seventeen studies (77%) reported
‘loss to follow up’ data regarding outcome measurements, which ranged from 0% to 15.6% (median 0.8%).
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Fig. 1 Flow chart showing total number of retrieved citations, reasons for exclusion and the number of studies included in the final analysis

The overall risk of bias of the 22 included studies is
shown in Fig. 2.
Inter-rater agreement (between authors KM and JC)
was high for the study characteristics based on independently abstracted data (80.7%, p <0.001), which was
further strengthened by consultation (95.5%, Kappa 0.88,
p <0.001). The remaining differences were resolved by
consensus among all authors.
d. Assessment of adherence

A definition of ‘compliance’ was provided in only one of
the included studies [9], which specified it as “at least
80% the scheduled intervention or placebo tablets having
been taken since the previous follow-up”.
Six studies (27%) reported to have measured patient
level medication adherence out of which five studies
(23%) [8–10, 19, 28] provided individual adherence results. Another study [31] suggested that it measured
adherence, but no results were provided. Estimates of
medication possession by ‘pill count’ or verifying ‘returned
drug boxes’ was used to assess adherence in all the six studies. Medication adherence was addressed to some extent in
the following seven studies: four studies [11, 14, 21, 30] excluded patients who were known to be non-compliant with
their medication; two studies [14, 32] reported average
blood test results as an indicator of adherence rather than
providing individual patient adherence; and one study [17]
provided results of ‘analysis with lag censoring’ where
data were censored, six months after patients discontinued the intervention (for different reasons including
non-adherence).

e. Adherence reporting and trial drug discontinuation
due to potential non-adherence

Among the five studies reporting measures of individual level medication adherence [8–10, 19, 28], the
reported adherence – described as the proportion of
patients remaining adherent to medications - varied
from between 65 to 92% in the intervention arm
(mean 81%), and 82 to 87% in the control arm (mean
84.5%). In these studies, discontinuation of trial drug
prior to study completion, ranged from 23 to 73% in
the intervention arm (mean 37.2%) and 24 to 74% in
the control arm (mean 37.2%). In one of these studies
[10], that reported 92% (intervention arm) and 86%
(control arm) adherence, 20% of participants in each
arm discontinued medications because of “other reasons” which included “patients not willing to continue
treatment” raising a suspicion of misclassification of
non-adherence. Another study [19] that listed 85%
adherence in the intervention and 87% in the placebo
arm, reported that only 77% of the dispensed bottles
were returned for pill count, raising the possibility of
overestimating adherence.
Nearly all studies (21 out of 22) provided data on study
drug discontinuation, with 0–73% (mean 33.2%; 95% CI,
22.0 to 44.5), in the intervention arm and 0–74% in the
control arm (mean 28.8%; 95% CI, 16.8 to 40.8, in the control arm) of participants discontinuing the study medication before the completion of the trial (Refer to Table 1).
The cited reasons for medication discontinuation other
than adverse events, death, kidney transplantation and
study drop-outs included: ‘non-adherence’ [14–17, 23];

Year of
publication

2011

2007

2012

2010

2013

2009

2009

2013

2007

2012

2014

2009

2006

2005

2007

2008

2006

Reference

Baigent et al. [9]

Block et al. [26]

Chertow et al. [17]

Cice et al. [24]

Di Iorio et al. [27]

Dixon et al. [28]

Fellstrom et al. [10]

Iseki et al. [25]

Jamison et al. [19]

Lok et al. [32]

Matsumoto et al. [30]

Nishimura et al. [29]

Righetti et al. [31]

Stegmayr et al. [11]

Suki et al. [15]

Suzuki et al. [22]

Svensson et al. [14]

HD

HD
206 (103/103)

366 (183/183)

2103 (1053/1050)

110 (53/57)b

HD & PDa

HD

88 (37/51)

129 (64 + 65)

309 (157/152)

HD

HD

HD

196 (99/97)

751 (372/379)b

HD & PDa

HD

469 (235/234)

2773 (1389/1384)

649 (321/328)

466 (232/234)

332 (165/167)

3883 (1948/1935)

HD

HD

HD

HD

HD

HD

127 (60/67)

3023 (1533/1490)b

HD & PDa

HD

Total N (Intervention/
Control)

Population

Omacor (3-PUFA)/Placebo

Any ARB/Usual care but no ARB

Sevalamer/Ca based binders

Atorvastatin/Placebo

Folic acid/Usual care

Nicorandil/Usual care but no
Nicorandil

Spironolactone/Usual care

Fish oil/Placebo

Folic acid + B6 + B12/Placebo

Olmesartan/Usual care but No
ARB or ACEI

Rosuvastatin/Placebo

Dipyridamole + Aspirin/Placebo

Sevalamer/Ca based binders

Add-on Telmisartan (to ACEI)/
Placebo

Cinacalcet/Placebo

Sevalamer/Ca based binders

Simvastain + Ezetimibe/Placebo

Therapy (Intervention/Control)

Negative

Positive

Negative

Negative

Positive

Positive

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Not reported

Positived

Positive

85%/87%

Not reported

Negative

Negative

92%/86%

83%/83%

Negatived
Negative

Not reported

Not reported

Not reported

Not reported

65%b in the
Inter-vention
group

Reported Adherence

Positive

Positive

Negative

Positive

Negativeb,c

Trial outcome

Non-adherent patients
excluded, Blood tests
supporting drug effect
reported, but patient
level adherence not
reported

Not addressed

TNA reported as cause
of therapy discontinuation

Non-adherent patients
excluded from participation

Reported as measured,
but not reported

Not addressed

Non-adherent patients
excluded from participation

Blood tests supporting
drug effect reported,
but not at patient level

Assessed by pill count
& reported

Not addressed

Assessed by pill count
& reported

Assessed by pill count
& reported

Not addressed

Not addressed

TNA reported as cause of
therapy discontinuation.
Reports lag censored
analysis after therapy
cessation

Specified as not checked

Run-in phase to identify
non-compliers

Addressing Adherence

27%/22%f,g

2%/2%f

48%/51%f,g,h

33%/6%f

72% e,f,h,I,j

0%/0%

29%/16%f

16%/16%i,j

27%/26%i

49% in interventionf,h

73%/74%f,g,h,i,j

30%/26%f,i

14%/15%i

16/11%f,i

67%/71%f,g,h

Not reported

33%/36%e,f

Drug discontinuation:
Intervention/Control
arms

Table 1 Summary of characteristics, study outcomes and details of addressing and reporting adherence in the randomized controlled trials included in the study
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2005

2009

2006

Wanner et al. [8]

Wilson et al. [16]

Zannad et al. [20]

HD

HD

HD

HD

HD

b

397 (196/201)

1354 (680/674)

1255 (619/636)

251 (123/128)

80 (43/37)

c

Fosinopril/Placebo

Lanthanum/Usual care

Atorvastatin/Placebo

Amlodipine/Placebo

Candesartan/Usual care

Negative

Negative

Negative

Negative

Positive

d

Not reported

Not reported

80%/82%

Not reported

Not reported

Not addressed

Not addressed

Assessed by pill
count & reported

TNA reported as
cause of therapy
discontinuation

Non-adherent
patients excluded
from participation

4%/5%h

72%/53%f,g,h,i,j

23%/24%f

63%/65%f,g,h,i,j

0%/0%

The trial also included patient not on dialysis. The data given pertains to dialysis patients only. The trial was positive for the overall cohort. Cardiovascular or mortality outcome was a secondary outcome. eThe
result is for the overall cohort. fIncludes adverse events as a cause of drug discontinuation. gIncludes non-adherence as a cause of drug discontinuation. h Includes kidney transplantation as a cause of drug
discontinuation. iIncludes drop-out or loss to follow up as a cause of drug discontinuation. jIncludes death as a cause of drug discontinuation. HD Haemodialysis. PD Peritoneal dialysis. TNA Treatment non-adherence

2008

Tepel et al. [23]

a

2006

Takahashi et al. [21]

Table 1 Summary of characteristics, study outcomes and details of addressing and reporting adherence in the randomized controlled trials included in the study (Continued)
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Fig. 2 Risk of bias estimates of included trials

‘patient choice’ [8, 10, 14, 15, 17, 28]; ‘administrative reasons’ [8, 15, 17, 28]; and ‘other reasons’ [10, 14, 15] (which
appear to classify elements of non-adherence in different
categories).
The Consolidated Standards of Reporting of Trials
(CONSORT) flow diagram depicting patient flow during the study including dropouts was provided in 91%
of the studies. Out of this, three studies [9, 11, 31] did
not provide data on attrition after randomization of
participants in the trial flow diagram. While nine trials
[8, 10, 14, 15, 17, 23, 25, 28, 30] gave different reasons
for withdrawal from the study or trial drug discontinuation, only two [14, 23] studies have cited non-adherence
as a reason for attrition in the CONSORT diagram.
f. Cardiovascular/mortality outcomes and study
characteristics including adherence

Thirteen studies, which included 17, 224 participants,
found that the trialed medication was not significantly
more effective in improving the cardiovascular or mortality outcomes when compared to the controls. On the
other hand, the remaining nine studies, which included
2098 participants, found that the trialed medication did
have beneficial effects when compared to the study controls (Refer to Table 1).
All four trials evaluating lipid lowering agents resulted
in negative study outcomes, while studies of antihypertensive medications (three out of six studies positive) phosphate binding agents (two out of four trials
positive) and fish oil or B-vitamins (two out of four
trials positive) yielded mixed results. Two out of three
trials investigating cardiac drugs including anti-platelet
agents were positive, while the only large-scale trial
evaluating the impact of calcimimetics on cardiovascular

events was negative for the pre-specified primary outcome
(Refer to Table 1).
Thirteen out of the 21 trials that provided study-drug
discontinuation data, reported cessation rates of over 20%.
These trials were more likely to yield a negative study outcome (11 out of 13 trials with >20% discontinuation were
negative), when compared to the remaining eight trials
(two out of eight trials with <20% discontinuation were
negative), which had lower drug discontinuation (p =
0.018, Fisher’s exact test).
All the five trials that reported individual patient level
adherence returned a negative result for the cardiovascular
outcomes in patients with end-stage renal failure undergoing dialysis. All these studies had low risk of bias estimates
for the various domains of study characteristics described
in section 4 c, above. One of these trials [9] which reported
advanced kidney disease and dialysis patients’ adherence
data separately, showed that non-dialysis patients had an
average adherence of 73%, with a higher level of adherence
of 76% among a sub-set of patients with a MDRD estimated GFR over 60mls/minute. The overall study drug use
were lower in the dialysis patients with an average adherence of 65%. The outcomes of this study were positive for
patients who were not on dialysis and for the overall
cohort, but negative for the dialysis patients.

g. Response from authors

We contacted seventeen authors by email, when the
study did not report information about measured adherence and seven authors responded. Six of the respondents had not evaluated adherence in their study,
while one [11] had measured patient level adherence
with an adherence of 83% for intervention and 81% for
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control arms. The study used ‘pill count’ as the method
of measuring adherence.

Discussion
In this systematic review, we sought to examine, how
the issue of medication adherence was assessed, reported
and addressed in dialysis patient trials evaluating cardiovascular or mortality outcomes. Non-adherence to therapy is important in the treatment of dialysis patients,
because, at the individual patient level, it can lead to
poor clinical outcomes [4] and in a clinical trial setting,
a high degree of non-adherence can lead to failure to
detect a true treatment effect [18]. To our knowledge
this is the first systematic review, exploring the problem
of non-adherence in dialysis patient trials and we have
noted striking inconsistencies and inadequacies in the
way in which medication adherence was reported, assessed
and addressed in the eligible trials.
We noted that only 27% of the included trials have
measured medication adherence to any extent and 23%
reported the results of adherence based on medication
possession. The low prevalence of individual patient
level adherence reporting, probably reflects a failure to
recognize the importance of treatment adherence as a
major factor influencing clinical outcomes. It is also
possible that in many of the trials cited in this review,
medication adherence was actually measured, but not
reported, as part of the findings. The adherence reporting, we observed in dialysis patient trials is somewhat
consistent with the systematic review findings of Gossec
et al. [18], evaluating the treatment adherence in six
chronic diseases; namely HIV, Diabetes, Rheumatoid
arthritis, Asthma, Hypertension and Osteoporosis. They
found that medication adherence was assessed in 33%
of the included trials, while only 25% of the trials provided results of adherence.
Consolidated Standards of Reporting Trials (CONSORT)
was developed in 1996 and updated in 2001 and 2010 to
improve the quality of reporting of RCTs [34]. The consensus statement has highlighted the importance of
distinguishing attrition, as a result of loss to follow up,
which is often unavoidable, from exclusions due to
other reasons such as withdrawal from treatment and
poor adherence to trial intervention [34]. The CONSORT
flow diagram illustrating patient flow through the trial
including components of attrition is frequently presented
in publications, but the information given is often not
detailed enough to ascertain the true extent and nature
of non-adherence [35]. The flow diagram was provided
in most of the included trials but the information was
highly inconsistent making it difficult to compare
between studies.
In our review, we observed that discontinuation of
study medication was common but the reporting of
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reasons for discontinuation were not consistent between
studies. The cited reasons like ‘patient choice’, ‘administrative reasons’ and ‘other reasons’ reported in the included
trials appear to classify elements of non-adherence under
different categories. This makes it difficult to get an accurate estimate of this problem in any given study and to
compare these estimates between studies. Our review suggests that trials with a study-drug discontinuation of over
20% are more likely to yield negative study outcomes. The
loss of statistical power due to high drop-out or drug discontinuation can lead to false negative outcome results
[18]. In this review, since there was no consistent reporting of the causes of drug discontinuation between studies
and only a small proportion of studies reported measuring
adherence, we were unable to estimate the true prevalence
of non-adherence and its contribution to discontinuation
between studies. This made the assessment of their impact
on study outcomes virtually impossible.
Some degree of non-adherence is inevitable during the
conduct of any intervention trial. Addressing nonadherence can be considered in the design, conduct or
analysis phase of the trial. Excluding patients who are likely
to be non-adherent, is the most efficient strategy in the
design phase and this was utilized by four [11, 14, 21, 30]
trials included in this review. Though patients who participate in the trial may be more motivated to adhere to the
prescribed treatment than those in the general population,
the intensity of the trial protocol may precipitate nonadherence [35]. Liaising with the patient’s caregivers to
elicit a history of poor treatment compliance has been
used as a screening strategy, but the inherent difficulty
in recognizing adherence in routine clinical practice
may reduce its reliability. Screening during a run-in phase
before randomization to unmask non-adherent behavior
to exclude non-compliers, is another approach and was
reported to have been used in one (8) of the studies
included in this review. However, these methods are not
foolproof and there is no guarantee that patients selected
in this manner will remain adherent to medications
throughout the RCT study period.
Efforts to increase the medication compliance during
the conduct of the study in dialysis patients pose
several challenges. Dialysis patients are frequently frail
and chronically ill with several comorbidities and a
heavy pill burden, which predispose to drop out due to
trial fatigue [17]. Increasing complexity of treatment is
an important factor that precipitates non-adherence
[1]. These factors are highly relevant to the participants
in the current systematic review.
Methods to address the effect of non-compliance in
the analysis phase of the trial are prone to bias. In our
review, 91% of the included trials were analyzed as
“intention to treat”. When the level of non-adherence is
high, the principle of assigning success or failure to an
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intervention, which was never received by the subject
has some limitations. However, analysis by actual treatment
received (TR) invalidates the assumptions underlying
randomization and thereby the probabilistic meaning of
reported p-values [36]. Despite this serious limitation,
analysis by TR has been tried in several forms in trials
where non-adherence is an issue: a) non-compliers can
be counted by the treatment they actually received
(‘naïve’ TR); b) non-compliers can be excluded; or c)
non-compliers can be treated as censored at the time
or shortly after they have stopped the treatment being
tested [36]. One of the studies [17] included in our
review has reported analysis with lag censoring, where
data was censored six months after participants discontinued the study drug, and showed significant improvements in hazards of the primary composite outcome
for the active treatment, while the ‘intention to treat’
analysis was negative. Estimators of the effect size in
analysis with lag censoring, may however be biased, as
analysis by TR is constrained by the same limitations as
in observational epidemiology, such as confounding [36].
Nevertheless, in the setting of high trial drug discontinuation, especially for non-protocol specified reasons, such
pragmatic approaches should be considered in context.
It is important to understand the difference between
“efficacy”, which implies whether a specific intervention
works under ideal circumstances and “effectiveness”
which denotes its effect in the ‘real-world’. It could be
argued that non-adherence is a "real-world" issue and in
order to understand how drugs perform in the real
world, it may be necessary to allow for non-adherence to
occur in a clinical trial, as it occurs in usual clinical
practice. However, failure to recognize and account for
non-adherence in a clinical trial setting, especially when
it is frequent, can mask the efficacy of the intervention
being investigated. Furthermore, if the level of nonadherence is recognized to be higher than originally
thought during the conduct of the clinical trial, false
negative outcomes could potentially be avoided by increasing the sample size, if feasible or extending duration of study follow up.
If a specific drug is less acceptable to the patient and
promotes non-adherence for this reason, its effectiveness
in the ‘real-world’ is going to be lower than the “efficacy”
demonstrated in a clinical trial setting.
Our study has both strengths and limitations. One of
the major strengths of this review is that it is the first analysis of adherence reporting in randomized control trials
evaluating cardiovascular or mortality outcomes in dialysis
patients. Another strength is that our review examines the
means to address the vexing problem of non-adherence in
the setting of dialysis patient trials. From a limitations perspective, the number of eligible studies included in our
review was small and the overall reporting of adherence
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was even smaller. The inconsistency in reporting of adherence and causes of trial drug discontinuation made it difficult to compare studies and combined with the varied
nature of the pharmacological interventions made it
meaningless to derive a pooled estimate. We would recommend the adoption of a more comprehensive and uniform
approach to evaluating and reporting non-adherence in future clinical trials to assess its impact on outcomes. This
should include the development of a broadly acceptable
definition of non-adherence, consistent methodologies (like
pill count) to measure the problem and routine reporting
of measured adherence similar to other standard items reported as per CONSORT guidelines. Defining medication
adherence as the intake of more than 80% of the prescribed
treatment, as done by Baigent et al. [9] may be acceptable
for most situations, but a blanket approach is not appropriate – for instance, drugs like anti-HIV medications and
immunosuppressant drugs would warrant more stringent
criteria. We also recommend a standardized approach to
reporting causes of trial drug discontinuation, which will help
us to compare the impact of different causes of therapy discontinuation on outcomes between different trials. Adverse
events, which may or may not be related to the medication,
are important causes of non-adherence and consistent
reporting of the causes of non-adherence is the only way to
evaluate their contribution to this problem. Considering the
heterogeneous nature of the problem of adherence and treatment discontinuation, these strategies pose difficult challenges, but are nevertheless possible to achieve.

Conclusions
In this systematic review of RCTs evaluating interventions targeted at improving clinical cardiovascular outcomes for dialysis patients, we identified inadequacies in
the medication adherence reporting and inconsistencies
in the reporting of causes contributing to study drug discontinuation. We also observed that the trials with high
study drug discontinuation were more likely to yield
negative study outcomes. We therefore recommend a
more comprehensive and consistent approach to measuring and reporting adherence and the causes of study
drug discontinuation in future trials, which will help to
clarify the true impact of poor treatment adherence on
the clinical outcomes of this vulnerable population.
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